97176 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
Anti-TCR antibody molecules and uses thereof
#302Bispecific Molecules That Are Immunoreactive With Immune Effector Cells That Express An Activating Receptor And An Antigen Expressed By A Cell Infected By A Virus And Uses Thereof
#303ANTI-TCR ANTIBODY MOLECULES AND USES THEREOF
#304MULTI-CHAIN CHIMERIC POLYPEPTIDES AND USES THEREOF
#305ANTI-TCR ANTIBODY MOLECULES AND USES THEREOF
#306Anti-VEGF protein compositions and methods for producing the same
#307Anti-IL1RAP antibody
#308ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF
#309MULTIFUNCTIONAL MOLECULES THAT BIND TO CD33 AND USES THEREOF
#310NEONATAL FC RECEPTOR BINDING AFFIMERS
#311ANTI-FCRH5 ANTIBODIES
#312IL-2 SUPERAGONISTS IN COMBINATION WITH ANTI-PD-1 ANTIBODIES
#313Fc variant with enhanced affinity to Fc receptors and improved thermal stability
#314Anti-FcRn Antibodies
#315LIGAND-BINDING FUSION PROTEINS
#316Anti-VEGF protein compositions and methods for producing the same
#317ARTICLES OF MANUFACTURE COMPRISING ANTI PD-L1 ANTIBODIES AND THEIR USE IN THERAPY
#318IgE Antibody with Fcgamma Receptor binding
#319COMPOSITIONS AND METHODS FOR CROSSLINKING FC RECEPTORS
#320METHODS OF TREATING WARM AUTOIMMUNE HEMOLYTIC ANEMIA USING ANTI-FCRN ANTIBODIES
#321Anti-VEGF protein compositions and methods for producing the same
#322A NOVEL CD16+ NATURAL KILLER CELL AND A METHOD OF CULTURING CD16+ NATURAL KILLER CELL
#323METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
#324ANTI-TCR ANTIBODY MOLECULES AND USES THEREOF
#325Heterodimeric Fc-fused proteins
#326ANTI-TCR ANTIBODY MOLECULES AND USES THEREOF
#327STABLE COMPOSITIONS OF FC MULTIMERS
#328Chimeric Antigen Receptor and Natural Killer Cells Expressing Same
#329ANTI-TCR ANTIBODY MOLECULES AND USES THEREOF
#330Chimeric antigen receptors targeting Fc receptor-like 5 and uses thereof
#331MATERIALS AND METHODS FOR POLYMERIC ANTIBODY RECEPTOR TARGETING
#332ANTI-CD3 ANTIBODIES AND METHODS OF USE
#333RECOMBINANT MONOVALENT ANTIBODIES AND METHODS FOR PRODUCTION THEREOF
#334Anti-VEGF protein compositions and methods for producing the same
#335ANTIGEN-BINDING MOLECULE FOR PROMOTING ELIMINATION OF ANTIGENS
#336METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS IN IGG4-RELATED DISEASES
#337Anti-VEGF protein compositions and methods for producing the same
#338IL-15-based fusions to IL-12 and IL-18
#339IgE Antibody with FcRn binding
#340MULTI-SPECIFIC BINDING PROTEINS THAT BIND CD33, NKG2D, AND CD16, AND METHODS OF USE
#341Binding molecules specific for FcγRIIA and uses thereof
#342Bi-Specific Monovalent Fc Diabodies That Are Capable of Binding CD32B and CD79b and Uses Thereof
#343MULTIMERIC ANTIBODIES WITH ENHANCED SELECTIVITY FOR CELLS WITH HIGH TARGET DENSITY
#344NK ENGAGER COMPOUNDS THAT BIND VIRAL ANTIGENS AND METHODS OF USE
#345CD3 BINDING MOLECULES
#346AGLYCOSYLATED ANTIBODY Fc REGION FOR TREATING CANCER
#347METHOD FOR THE PRODUCTION OF BISPECIFIC FCYRIII X CD30 ANTIBODY CONSTRUCT
#348NEUTRALIZING ANTI-SARS-CoV-2 ANTIBODIES AND USE THEREOF
#349HETERODIMERIC PROTEINS AND METHODS FOR PRODUCING AND PURIFYING THEM
#350IMMUNOTHERAPY COMPOUNDS AND METHODS
#351MATERIALS AND METHODS FOR MULTIDIRECTIONAL BIOTRANSPORTATION
#352ANTIGEN-BINDING MOLECULE FOR PROMOTING CLEARANCE FROM PLASMA OF ANTIGEN COMPRISING SUGAR CHAIN RECEPTOR-BINDING DOMAIN
#353USE OF ANTI-FCRN ANTIBODIES IN THE TREATMENT OF PEMPHIGHUS AND PEMPHIGOID DISEASES
#354Anti-SIRPa antibodies and methods of use thereof
#355Covalent Diabodies and Uses Thereof
#356Anti-VEGF protein compositions and methods for producing the same
#357ANTI-CTLA-4 ANTIBODIES AND METHODS OF USE THEREOF
#358SIALIDASE-RESISTANT SACCHARIDE AND METHOD OF MAKING AND USING THE SAME
#359IMMUNOTHERAPIES
#360ANTIBODY COMBINATIONS FOR TREATMENT OF CANCER IN SPECIFIC PATIENTS
#361FCRN ANTIBODIES AND METHODS OF USE THEREOF
#362NOVEL IMMUNOCONJUGATES
#363Anti-IL1RAP antibody
#364Anti-VEGF protein compositions and methods for producing the same
#365Anti-VEGF protein compositions and methods for producing the same
#366Anti-VEGF protein compositions and methods for producing the same
#367AFFINITY MATURATED TAG72 SPECIFIC SINGLE CHAING ANTIBODIES
#368TRIPLE GLUCAGON/GLP-1/GIP RECEPTOR AGONIST
#369METHOD FOR PURIFYING FC REGION-MODIFIED ANTIBODY
#370PHARMACEUTICAL FORMULATIONS AND DOSAGE REGIMENS FOR MULTI-SPECIFIC BINDING PROTEINS THAT BIND HER2, NKG2D, AND CD16 FOR CANCER TREATMENT
#371CLAUDIN-6 BISPECIFIC ANTIBODIES
#372MODULATING ANTIBODY EFFECTOR FUNCTIONS
#373FcgammaRIIB-Specific Antibodies and Methods of Use Thereof
#374VARIANT FC DOMAINS AND USES THEREOF
#375ANTIBODIES SPECIFIC TO FCRN
#376METHODS AND COMPOSITIONS FOR TREATMENT OF LUPUS
#377Anti-VEGF protein compositions and methods for producing the same
#378PROTEINS BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
#379METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
#380FCRN ANTIBODIES AND METHODS OF USE THEREOF
#381METHOD FOR THE TREATMENT OF MYASTHENIA GRAVIS
#382Anti-CD94 antibodies and methods of use thereof
#383Methods for producing aflibercept in chemically defined media having reduced aflibercept variants
#384Complementary RNA linked bispecific T-cell engaging antibodies
#385Proteins binding NKG2D, CD16 and CLEC12A
#386HETERODIMERIC FC-FUSED PROTEINS
#387Antigen-Presenting Neutrophil-Derived Dendritic Cells and Methods of Use Thereof
#388Anti-VEGF protein compositions and methods for producing the same
#389STRUCTURED GELS
#390MULTI-SPECIFIC BINDING PROTEINS THAT BIND BCMA, NKG2D AND CD16, AND METHODS OF USE
#391Anti-TMPRSS2 antibodies and antigen-binding fragments
#392USE OF AGENTS CAPABLE OF INDUCING LC3-ASSOCIATED PHAGOCYTOSIS FOR TREATING SUSTAINED INFLAMMATION IN PATIENTS SUFFERING FROM CHRONIC LIVER DISEASE
#393ANTIBODY POLYPEPTIDES THAT ANTAGONIZE CD40L
#394NOVEL AGONISTIC ANTI TNFR2 ANTIBODY MOLECULES
#395ANTI-TCR ANTIBODY MOLECULES AND USES THEREOF
#396FcRn antibodies and methods of use thereof
#397IL-15-based fusions to IL-12 and IL-18
#398Humanized and affinity matured antibodies to FcRH5 and methods of use
#399IMMUNOGLOBULIN A ANTIBODIES AND METHODS OF PRODUCTION AND USE
#400CELLS EXPRESSING ANTIBODIES TARGETING HUMAN IMMUNODEFICIENCY VIRUS AND METHODS OF USING THE SAME
#401Anti-VEGF protein compositions and methods for producing the same
#402Tandem diabody for CD16A-directed NK-cell engagement
#403Materials and methods for multidirectional biotransportation in virotherapeutics
#404Compositions and methods related to engineered Fc constructs
#405Anti-VEGF protein compositions and methods for producing the same
#406Methods for producing aflibercept in chemically defined media having reduced aflibercept variants
#407TETRAHEDRAL ANTIBODIES
#408Long-acting exendin-4 and use thereof
#409Anti-VEGF protein compositions and methods for producing the same
#410Anti-VEGF protein compositions and methods for producing the same
#411Anti-VEGF protein compositions and methods for producing the same
#412Agonistic anti TNFR2 antibody molecules
#413METHODS OF TREATING GRAVES' OPHTHALMOPATHY USING ANTI-FCRN ANTIBODIES
#414METHOD FOR EVALUATING THE PRESENCE OF A VIRAL RESERVOIR, AND EVALUATING THE EFFICACY OF A DRUG AGAINST SAID RESERVOIR
#415METHODS AND COMPOSITIONS FOR TRANSDUCING LYMPHOCYTES AND REGULATING THE ACTIVITY THEREOF
#416ENGINEERED IGA ANTIBODIES AND METHODS OF USE
#417ANTIBODY CONJUGATE, AND RELATED PHARMACEUTICAL COMPOSITION AND APPLICATION
#418METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
#419THERAPEUTIC COMPOUNDS AND METHODS
#420METHOD FOR ENGINEERING IMMUNOGLOBULINS
#421NK engager molecules and methods of use thereof
#422Anti-human CD89 antibodies and uses thereof
#423ENGINEERED FC
#424ANTIBODIES TARGETING FC RECEPTOR-LIKE 5 AND METHODS OF USE
#425Engineered IGA antibodies and methods of use
#426ANTIBODY COMPOSITION
#427DLL3 SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC COMPOSITIONS THEREOF
#428Suppressing IgE-Mediated Allergy by Desensitization with Monovalent Anti-FCeR1a Monoclonal Antibody
#429Anti-VEGF protein compositions and methods for producing the same
#430PROTEIN BINDING NKG2D, CD16 AND A FIBROBLAST ACTIVATION PROTEIN
#431Kit containing medium for culturing natural killer cells and method of effectively culturing natural killer cells using the same
#432Engineered antibody Fc variants for enhanced serum half life
#433CD31SHED AS A MOLECULAR TARGET FOR IMAGING OF INFLAMMATION
#434COMPOSITIONS AND METHODS FOR MODULATING AN IMMUNE RESPONSE
#435COMBINED USE OF FC GAMMA RIIB (CD32B) AND CD20 SPECIFIC ANTIBODIES
#4365T4 SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC COMPOSITIONS THEREOF
#437FCRN ANTIBODY COMPOSITIONS
#438MULTI-SPECIFIC BINDING CONJUGATE, RELATED PHARMACEUTICAL COMPOSITIONS AND USE
#439Anti-CD20 glycoantibodies and uses thereof
#440Compositions and methods of treating cancer with chimeric antigen receptors
#441IgA mediated killing of aberrant cells by CD47- SIRPalpha checkpoint inhibition of neutrophils
#442IL-15 Variants and Uses Thereof
#443METHODS OF MAKING NATURAL KILLER CELLS AND USES THEREOF
#444MULTI-SPECIFIC BINDING PROTEINS THAT BIND BCMA, NKG2D AND CD16, AND METHODS OF USE
#445CONDITIONALLY ACTIVE PROTEINS WITH pH SELECTIVITY
#446Antibodies which bind Fc receptors (FcRn)
#447COMPOSITIONS OF FCRN ANTIBODIES AND METHODS OF USE THEREOF
#448PROTEINS BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
#449HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
#450Anti-TCR antibody molecules and uses thereof
#451IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS
#452PROTEINS BINDING NKG2D, CD16, AND EGFR, CCR4, OR PD-L1
#453Fc-binding protein exhibiting improved alkaline resistance, method for producing said protein, antibody adsorbent using said protein, and method for separating antibody using said antibody adsorbent
#454USES OF NK CELL ENGAGING ANTIBODY FUSION CONSTRUCTS FOR TREATMENTS
#455ONCOLYTIC VIRUS PLATFORM TO TREAT HEMATOLOGICAL CANCER
#456PROTEINS BINDING NKG2D, CD16 AND P-CADHERIN
#457ANTI-TMPRSS2 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS
#458PROTEINS BINDING NKG2D, CD16 AND AN ANTIGEN ASSOCIATED WITH TUMORS, MDSCS AND/OR TAMS
#459Artificial Protein Containing Antigen-Binding Region of Antibody and Being Fused With Physiologically Active Peptide
#460Anti-VEGF protein compositions and methods for producing the same
#461MULTI-SPECIFIC BINDING PROTEINS AND IMPROVEMENTS THEREON
#462VARIANTS WITH FC FRAGMENT HAVING AN INCREASED AFFINITY FOR FCRN AND AN INCREASED AFFINITY FOR AT LEAST ONE RECEPTOR OF THE FC FRAGMENT
#463DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) IN PEDIATRIC PATIENTS
#464PROTEINS BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
#465IgG1 FC monomer and application thereof
#466Anti-VEGF protein compositions and methods for producing the same
#467Multi-specific binding proteins that bind HER2, NKG2D, and CD16, and methods of use
#468POLYMERIC IMMUNOGLOBULIN FUSION PROTEINS THAT TARGET LOW-AFFINITY FCγ RECEPTORS
#469LONG-ACTING CONJUGATE OF TRIPLE GLUCAGON/GLP-1/GIP RECEPTOR AGONIST
#470Anti-CD40 antibodies and uses thereof
#471TARGETED DELIVERY METHODS AND COMPOSITIONS FOR ANTIHISTAMINES
#472Bispecific CD16-binding molecules and their use in the treatment of disease
#473Anti-VEGF protein compositions and methods for producing the same
#474Cryopreserved NK cells preloaded with an antibody construct
#475Anti-variant Fc-region antibodies and method of use
#476THERAPEUTIC FCRN-BASED BISPECIFIC MONOCLONAL ANTIBODIES
#477MULTISPECIFIC BINDING PROTEINS TARGETING CEA
#478MULTISPECIFIC BINDING PROTEINS TARGETING CAIX, ANO1, MESOTHELIN, TROP2, OR CLAUDIN-18.2
#479PROTEINS BINDING CD33, NKG2D AND CD16
#480Methods and Compositions for Reducing Immunogenicity By Non-Depletional B Cell Inhibitors
#481Engineered IGA antibodies and methods of use
#482Engineered IgA antibodies and methods of use
#483Targeted prevention of maternal to foetal vertical transmission of infection
#484Multispecific antigen-binding molecules binding to a target and an internalizing effector protein that is CD63 and uses thereof
#485Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof
#486Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of use
#487Chimeric antibody/T-cell receptor constructs and uses thereof
#488Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof
#489CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORS AND SECONDARY EFFECTORS AND USES THEREOF
#490COMBINATION THERAPY OF CANCER INVOLVING MULTI-SPECIFIC BINDING PROTEINS THAT ACTIVATE NATURAL KILLER CELLS
#491Methods and means for the production of Ig-like molecules
#492Multi-chain chimeric polypeptides and uses thereof
#493Multi-chain chimeric polypeptides and uses thereof
#494Multi-specific ligand binders
#495Antibody variable domains targeting the NKG2D receptor
#496ANTIBODIES TARGETING CD32B AND METHODS OF USE THEREOF
#497Methods and Compositions for Reducing Immunogenicity By Non-Depletional B Cell Inhibitors
#498FVIII CHIMERIC ANTIGEN RECEPTOR TREGS FOR TOLERANCE INDUCTION IN HEMOPHILIA A
#499METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
#500METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
#501MULTIVALENT HETEROMULTIMER SCAFFOLD DESIGN AND CONSTRUCTS
#502FC-BINDING PROTEIN HAVING IMPROVED ACID STABILITY, PRODUCTION METHOD FOR SAID PROTEIN, AND ANTIBODY-ADSORBING AGENT USING SAID PROTEIN
#503Methods and compositions relating to epoxide hydrolase genes
#504Aptamer based affinity capture methods for the selective enrichment of human immunoglobulin Fc domains
#505Synthetic extracellular vesicles for novel therapies
#506Therapeutic agents and methods for enhancing immune responses in tumor microenvironment
#507UNIVERSAL ABT COMPOUNDS AND USES THEREOF
#508Anti-CD137 antibodies and uses thereof
#509Multispecific antibodies that target HIV GP120 and CD3
#510BCMA-TARGETING CHIMERIC ANTIGEN RECEPTOR, AND USES THEREOF
#511CYSTEINE PEPTIDE-ENABLED ANTIBODIES
#512NOVEL COMBINATION AND USE OF ANTIBODIES
#513Compositions for increasing half-life of a therapeutic agent in canines and methods of use
#514IgG Fc variants for veterinary use
#515Anti-CTLA-4 antibodies and methods of use thereof
#516Bispecific molecules comprising an HIV-1 envelope targeting arm
#517CD33-binding polypeptides and uses thereof
#518MULTISPECIFIC ANTIGEN BINDING PROTEINS
#519Anti-CD3 antibodies and methods of use
#520Anti-CD3 antibodies and methods of use
#521FcRn antibodies and methods of use thereof
#522COMPOUNDS AND METHODS FOR TUMOUR-SPECIFIC CELL DEPLETION
#523PROTEINS BINDING NKG2D, CD16, AND C-TYPE LECTIN-LIKE MOLECULE-1 (CLL-1)
#524PROTEINS BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
#525Antibody variants
#526Disrupting FC receptor engagement on macrophages enhances efficacy of anti-SIRPalpha antibody therapy
#527COMBINATION THERAPY
#528ANTIBODIES WITH ENHANCED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY ACTIVITY, METHODS OF THEIR PRODUCTION AND USE
#529PROTEINS BINDING GD2, NKG2D AND CD16
#530PROTEINS BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
#531Proteins binding HER2, NKG2D and CD16
#532PROTEINS BINDING NKG2D, CD16, AND EGFR, HLA-E, CCR4, OR PD-L1
#533Compositions for increasing half-life of a therapeutic agent in canines and methods of use
#534HUMANIZED AFFINITY MATURED ANTI-FcRn ANTIBODIES
#535Multi-chain polypeptide-containing tri-specific binding molecules
#536Tri-specific binding molecules that specifically bind to multiple cancer antigens
#537Modified J-chain
#538Anti-FCRH5 antibodies
#539HUMANIZED AFFINITY MATURED ANTI-FcRn ANTIBODIES
#540Bispecific antibody for cancer immunotherapy
#541MODIFIED ANTIBODY CONSTANT REGION
#542PROTEINS BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
#543PROTEINS BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
#544Therapeutic compounds and methods
#545METHOD FOR THE TREATMENT OF IMMUNE THROMBOCYTOPENIA
#546FcgammaRIIB-Specific Antibodies and Methods of Use Thereof
#547Heterodimeric Fc variants
#548Anti-transferrin receptor antibodies and methods of use
#549ANTIGEN-BINDING MOLECULE INDUCING IMMUNE RESPONSE TO TARGET ANTIGEN
#550NK cell engaging antibody fusion constructs
#551Antibody binding to FCRN for treating autoimmune diseases
#552Nucleic acids encoding anti-neonatal Fc receptor (FcRn) antibodies
#553Deimmunized Serum-Binding Domains and Their Use in Extending Serum Half-Life
#554CD30 bispecific antibodies and method of immunotherapy of CD30+ malignancies
#555ANTIBODY HEAVY CHAIN VARIABLE DOMAINS TARGETING THE NKG2D RECEPTOR
#556MITIGATING Fc-Fc RECEPTOR INTERACTIONS IN CANCER IMMUNOTHERAPY
#557ANTIGEN BINDING RECEPTOR FORMATS
#558Antigen binding receptors specific for mutated Fc domains
#559Ingestible device with expandable enclosure
#560ANTIBODIES TARGETING A LIGAND FROM AN IMMUNE CHECKPOINT, WITH AN FC FRAGMENT HAVING AN IMPROVED AFFINITY FOR CD16A
#561THERAPEUTIC COMPOUNDS AND METHODS
#562ANTIBODY CONJUGATE, AND RELATED PHARMACEUTICAL COMPOSITION AND APPLICATION
#563METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
#564Multi-chain chimeric polypeptides and uses thereof
#565Combined use of FcγRIIb (CD32B) and CD20 specific antibodies
#566ANTIBODIES AND ANTIBODY FRAGMENTS FOR SITE-SPECIFIC CONJUGATION
#567Anti-Fc epsilon-R1 alpha (FcεR1α) antibodies, bispecific antigen-binding molecules that bind FcεR1α and CD3, and uses thereof
#568Pharmaceutical composition
#569MULTISPECIFIC ANTIGEN BINDING PROTEINS
#570COMPOSITIONS AND METHODS FOR MODULATING AN IMMUNE RESPONSE
#571METHODS TO MANIPULATE ALPHA-FETOPROTEIN (AFP)
#572Method for isolating HIV reservoir cells expressing CD32a cell marker
#573COMPOSITIONS AND METHODS FOR CROSSLINKING FC RECEPTORS
#574PROTEINS BINDING PSMA, NKG2D AND CD16
#575Compositions and methods for treating immune thrombocytopenia
#576COMPOSITIONS AND METHODS FOR MODULATING AN IMMUNE RESPONSE
#577Methods and means for the production of ig-like molecules
#578Combination of an anti-CD16A antibody with a cytokine
#579Fc variants
#580Methods to manipulate alpha-fetoprotein (AFP)
#581Binding molecules specific for FcγRIIA and uses thereof
#582PROTEINS BINDING BCMA, NKG2D AND CD16
#583Multivalent heteromultimer scaffold design and constructs
#584Methods and therapeutics comprising ligand-targeted ELPs
#585Binding molecules against BCMA and uses thereof
#586Multi-specific binding proteins that bind NKG2D, CD16, and a tumor-associated antigen for activation of natural killer cells and therapeutic uses thereof to treat cancer
#587Anti-SIRPA antibodies and methods of use thereof
#588Aglycosylated antibody Fc region for treating cancer
#589Tandem diabody for CD16A-directed NK-cell engagement
#590CHIMERIC ANTIGEN RECEPTOR AND NATURAL KILLER CELLS EXPRESSING SAME
#591METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
#592HETERODIMERIC ANTIGEN BINDING PROTEINS
#593NOVEL IMMUNOCONJUGATES
#594Methods for the Use of CD32B x CD79B-Binding Molecules in the Treatment of Inflammatory Diseases and Disorders
#595Immunoconjugates
#596Affinity maturated TAG72 specific single chain antibodies
#597METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
#598Humanized and affinity matured antibodies to FcRH5 and methods of use
#599Anti-TREM2 antibodies and methods of use thereof
#600MULTISPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOF